ANI executive sells 6,572 ANI Pharmaceuticals shares

ANI Pharmaceuticals senior executive Krista Davis reported open-market sales of company stock.

Rhea-AI Filing Summary

ANI Pharmaceuticals senior executive Krista Davis reported open-market sales of company stock. As SVP and Chief HR Officer, she sold 6,572 shares of ANI Pharmaceuticals common stock in two transactions at prices of $74.13 and $75.00 per share. These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 18, 2025, indicating they were scheduled in advance rather than timed discretionarily. Following the transactions, Davis directly holds 51,946 shares of ANI Pharmaceuticals common stock.

Insider Trade Summary 10b5-1

Net Seller: 6,572 shares

Net Sell 2 txns

Insider Davis Krista

Role SVP, CHIEF HR OFFICER

Sold 6,572 shs ($488K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,087	$74.13	$377K
Sale	Common Stock	1,485	$75.00	$111K

Holdings After Transaction: Common Stock — 51,946 shares (Direct)

Footnotes (2)

1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2025.
2. F2. The shares were sold in multiple trades at prices ranging from $72.94 to $74.76. The price reported above reflects the weighted average sales price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ANI Pharmaceuticals (ANIP) report for Krista Davis?

ANI Pharmaceuticals reported that SVP and Chief HR Officer Krista Davis sold 6,572 shares of common stock in two open-market transactions. The trades occurred on March 6 and March 9, 2026, at prices around $74–$75 per share, under a pre-arranged Rule 10b5-1 plan.

At what prices did Krista Davis sell ANI Pharmaceuticals (ANIP) shares?

Krista Davis sold ANI Pharmaceuticals common stock at reported prices of $74.13 and $75.00 per share. A footnote explains that some shares were sold in multiple trades between $72.94 and $74.76, with $74.13 reflecting the weighted average sales price for those transactions.

How many ANI Pharmaceuticals (ANIP) shares does Krista Davis hold after these sales?

After the reported transactions, Krista Davis directly holds 51,946 shares of ANI Pharmaceuticals common stock. This figure reflects her position following the open-market sales of 6,572 shares disclosed in the Form 4, based on the totals listed after each transaction entry.

Were Krista Davis’s ANI Pharmaceuticals (ANIP) stock sales under a Rule 10b5-1 plan?

Yes, the filing states that the sales were made under a Rule 10b5-1 trading plan adopted on September 18, 2025. Such plans allow insiders to schedule future trades in advance, helping separate trading decisions from day-to-day information they may receive.

What is the nature of the Form 4 transactions for ANI Pharmaceuticals (ANIP)?

The Form 4 shows two non-derivative open-market sales of ANI Pharmaceuticals common stock by executive Krista Davis. Both transactions are coded “S” for sale and are described as sales in the open market or private transactions, with direct ownership reported after the trades.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/10/2026 - 04:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davis Krista

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CHIEF HR OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/06/2026		S(1)		1,485	D	$75	57,033	D
Common Stock	03/09/2026		S(1)		5,087	D	$74.13(2)	51,946	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2025.

2. The shares were sold in multiple trades at prices ranging from $72.94 to $74.76. The price reported above reflects the weighted average sales price.

Remarks:

	/s/ Krista Davis, by attorney-in-fact Meredith W. Cook	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.